Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033618
Status:
COMPLETED
Last Update Posted:
2013-02-27
First Post:
2002-04-09
Brief Title:
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Randomized Phase II Study of BMS-247550 NSC 710428 Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
PRIMARY OBJECTIVES
I To determine the response rate and toxicity of BMS-247550 given in two dosing schedules in taxane-naïve and taxane-exposed patients
II To provide information about the response rate and toxicity of BMS-247550 given in two dosing schedules
SECONDARY OBJECTIVES
I To measure surviving expression and correlate with the therapeutic responsiveness to BMS-247550
II To determine the changes in tumor vascular density and endothelial cell apoptosis in response to therapy and the correlation of these changes to outcome
OUTLINE This is a randomized study Patients are stratified according to prior taxane therapy yes vs no and ECOG performance status 0 vs 1 Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive ixabepilone IV over 1 hour on days 1-5 Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
Arm II Patients receive ixabepilone IV over 1 hour on days 1 8 and 15 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
In both arms patients achieving complete response CR receive 2 additional courses past CR if a minimum of 6 courses have been administered
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
I To determine the response rate and toxicity of BMS-247550 given in two dosing schedules in taxane-naïve and taxane-exposed patients
II To provide information about the response rate and toxicity of BMS-247550 given in two dosing schedules
SECONDARY OBJECTIVES
I To measure surviving expression and correlate with the therapeutic responsiveness to BMS-247550
II To determine the changes in tumor vascular density and endothelial cell apoptosis in response to therapy and the correlation of these changes to outcome
OUTLINE This is a randomized study Patients are stratified according to prior taxane therapy yes vs no and ECOG performance status 0 vs 1 Patients are randomized to 1 of 2 treatment arms
Arm I Patients receive ixabepilone IV over 1 hour on days 1-5 Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
Arm II Patients receive ixabepilone IV over 1 hour on days 1 8 and 15 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
In both arms patients achieving complete response CR receive 2 additional courses past CR if a minimum of 6 courses have been administered
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000069305 | REGISTRY | PDQ Physician Data Query | httpsreporternihgovquickSearchU10CA021115 |
| E2301 | None | None | None |
| U10CA021115 | NIH | None | None |